Phar­ma heavy­weight Pfiz­er step­ping in­to the prostate can­cer ring with Ab­b­Vie af­ter ink­ing a $4.2B al­liance with My­ovant

My­ovant $MY­OV is ring­ing out the old year with a big, new com­mer­cial part­ner.

Pfiz­er $PFE has stepped up with a $4.2 bil­lion deal to part­ner with the biotech on its new­ly ap­proved drug re­l­u­golix, freight­ing the deal up­front with $650 mil­lion in cash and an­oth­er $200 mil­lion re­served for reg­u­la­to­ry de­ci­sions as My­ovant looks to fol­low up its win for prostate can­cer with 2 oth­er OKs for uter­ine fi­broids and en­dometrio­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER